At the University of Michigan Comprehensive Cancer Center, researchers are experimenting with adding an IL-6 inhibitor to Herceptin therapy to prevent HER2-positive breast cancer patients from becoming resistant to the drug, reports Genetic Engineering & Biotechnology News. The Michigan researchers — whose work is published in Molecular Cell — found that breast cancer cells can switch on an IL-6 inflammatory pathway, which then promotes the development of cancer stem cells and leads to tumor growth independent of HER2, GEN says. Blocking the IL-6 pathway inhibits the propagation of these stem cells. In mouse studies, the team found that mice treated with an IL-6 inhibitor remained sensitive to Herceptin.
Fight the Resistance
Jul 21, 2012